Lakefront Biotherapeutics (GLPGF) Liabilities and Shareholders Equity (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $3.9 billion the latest figure, recorded in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 6.67% year-over-year to $3.9 billion in Q1 2026; TTM through Jun 2026 was $12.0 billion, a 31.53% decrease from a year earlier, with the FY2025 full-year figure at $3.8 billion, down 14.02% from the prior year.
• Liabilities and Shareholders Equity was $3.9 billion for Q1 2026 at Lakefront Biotherapeutics, roughly flat from $4.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $5.7 billion in Q1 2022 and troughed at $3.9 billion in Q1 2026.
• A 5-year average of $4.6 billion and a median of $4.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slipped 18.69% in 2022 and decreased 2.94% in 2023, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $4.8 billion in 2022, then dropped by 2.94% to $4.7 billion in 2023, then dropped by 5.74% to $4.4 billion in 2024, then retreated by 10.27% to $4.0 billion in 2025, then retreated by 0.43% to $3.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $3.9 billion (Q1 2026), $4.0 billion (Q4 2025), and $4.1 billion (Q3 2025), per Business Quant data.